Pharmaceutical

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-ti...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year.

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing reform under the Trump ad...

Currax Pharmaceuticals is taking its direct-to-consumer push national and partnering with patients to pitch its obesity treatment as a more affordable...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Mass...

President Donald Trump has doubled down on his plan to assess tariffs on imported pharmaceutical products, saying they will eventually reach 250%. The...

Supreme Group said the deal deepens its expertise in rare disease and pharma and expands the creative and omnichannel solutions it can deliver.

Raising awareness of medical products and services is a marathon, not a sprint, and Babson Diagnostics has therefore selected a star with plenty of st...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa has pulled further ahead.

Two years into CEO Bill Anderson's tenure, Bayer has reduced its head count by more than 12,000, with little slowdown in the pace of dismissals. In re...